Ginkgo Bioworks Holdings Inc (DNA)
0.8399
-0.03
(-3.52%)
USD |
NYSE |
Apr 24, 16:00
0.837
0.00 (0.00%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Cash from Investing (TTM): -80.69M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -80.69M |
| September 30, 2023 | -4.279M |
| June 30, 2023 | -47.38M |
| March 31, 2023 | -50.82M |
| December 31, 2022 | -67.39M |
| Date | Value |
|---|---|
| September 30, 2022 | -92.91M |
| June 30, 2022 | -76.93M |
| March 31, 2022 | -86.20M |
| December 31, 2021 | -73.26M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-92.91M
Minimum
Sep 2022
-4.279M
Maximum
Sep 2023
-64.43M
Average
-73.26M
Median
Dec 2021
Cash from Investing (TTM) Benchmarks
| Agenus Inc | 3.40M |
| Teladoc Health Inc | -156.35M |
| Sarepta Therapeutics Inc | -165.80M |
| Ultragenyx Pharmaceutical Inc | 168.00M |
| Apellis Pharmaceuticals Inc | -0.674M |